文献速递耳科与耳神经

5-羟色胺-去甲肾上腺素再摄取抑制剂治疗梅尼埃病的疗效:一项随机临床试验

Efficacy of a Serotonin-Norepinephrine Reuptake Inhibitor as a Treatment for Meniere Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项随机、双盲、安慰剂对照交叉先导研究在单个三级转诊中心纳入40例梅尼埃病患者,比较文拉法辛37.5 mg每日口服与安慰剂各8周的疗效。文拉法辛期与安慰剂期眩晕发作次数及生活质量指标均无显著差异。作者认为未来研究可能受益于不同给药方案、更大样本和更长疗程。

要点

  • 文拉法辛37.5 mg每日口服8周与安慰剂相比,眩晕发作次数无显著差异。
  • 生活质量量表(DHI、NVI、MDPOSI、SF-20、PSWQ、CFQ)评分两组间无显著差异。
  • 作者认为未来研究可能受益于不同给药方案、更大队列和更长疗程。

核心结论

  • 这项随机临床试验未能发现文拉法辛与安慰剂在发作次数及其他生活质量指标上的差异。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉先导研究,随访22周,在Charleston, South Carolina的单个三级转诊中心开展。
  • 182例患者接受筛查,40例梅尼埃病患者入组;平均(SD)年龄56.6(14.3)岁,22例(55%)为女性。
  • 患者于2020年2月至2023年9月入组;入组标准包括年龄18岁及以上、符合Barany标准的确诊梅尼埃病、上月至少2次发作等。
  • 干预为文拉法辛片37.5 mg每日口服8周或安慰剂片每日口服8周;第1组第一阶段接受安慰剂、第二阶段接受文拉法辛,第2组第一阶段接受文拉法辛、第二阶段接受安慰剂。

主要发现

  • 基线时每阶段平均(SD)发作13.8(10.1)次,文拉法辛期平均(SD)5.4(4.4)次(Δ8.4),安慰剂期平均(SD)5.0(4.6)次(Δ8.8)。
  • 文拉法辛组与安慰剂组在发作次数或生活质量指标上均未发现显著差异。

关键数值与推荐

  • 主要结局包括发作次数及以下量表评分:头晕残障量表(Dizziness Handicap Inventory)、神经心理性眩晕量表(Neuropsychological Vertigo Inventory)、梅尼埃病患者导向症状指数(Meniere Disease Patient-Oriented Symptom Index)、20项简表健康调查(20-Item Short Form Health Survey)、宾夕法尼亚州立忧虑问卷(Penn State Worry Questionnaire)、认知失败问卷(Cognitive Failure Questionnaire)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文报告为先导研究(pilot study)。
  • 作者在结论中提出未来研究可能受益于不同给药方案、更大队列和更长疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Meniere disease accounts for up to 15% of new vestibular diagnoses,; however, the optimal treatment has yet to be identified. A conservative treatment that would reduce or stop the vertigo episodes has not been identified. OBJECTIVE: To determine the efficacy of a serotonin-norepinephrine reuptake inhibitor, venlafaxine, compared to placebo in treating patients with Meniere disease. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, double-blind, placebo-controlled, crossover pilot study spanning 22 weeks of follow-up. The clinical trial took place at a single-center tertiary referral center in Charleston, South Carolina. Participants were eligible if they were 18 years or older, had definite Meniere disease criteria as defined by Barany criteria, had at least 2 episodes in the last month, had not received intratympanic gentamycin, skull base surgery, or radiation therapy to the head or neck, not currently taking diuretics for Meniere disease, not currently taking oral steroids, and not currently taking serotonin-modulating medication. Patients were enrolled between February 2020 and September 2023. INTERVENTIONS: Patients received either 1 venlafaxine tablet, 37.5 mg, taken daily by mouth for 8 weeks or 1 placebo tablet taken daily by mouth for 8 weeks. Group 1 received placebo during phase 1 of the trial and venlafaxine in phase 2 of the trial. Group 2 received venlafaxine during phase 1 of the trial and placebo in phase 2 of the trial. MAIN OUTCOMES AND MEASURES: The main outcomes included the number of episodes and scores on the following scales: Dizziness Handicap Inventory, Neuropsychological Vertigo Inventory, Meniere Disease Patient-Oriented Symptom Index, 20-Item Short Form Health Survey, Penn State Worry Questionnaire, Cognitive Failure Questionnaire. RESULTS: A total of 182 patients were screened, and 40 participants with Meniere disease enrolled in the trial. The mean (SD) age of participants was 56.6 (14.3) years, and 22 (55%) were female. Participants had a mean (SD) of 13.8 (10.1) episodes per phase at baseline, 5.4 (4.4) episodes (Δ8.4) during the venlafaxine phase, and 5.0 (4.6) episodes (Δ8.8) during the placebo phase. No significant difference was identified between venlafaxine and placebo groups in the number of episodes or quality-of-life metrics. CONCLUSIONS AND RELEVANCE: This randomized clinical trial failed to identify a difference between venlafaxine and placebo in number of episodes and other quality-of-life metrics. Future studies may benefit from different dosing regimens, larger cohorts, and longer lengths of therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04218123.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Rizk H, Monaghan NP, Shah S, et al. Efficacy of a Serotonin-Norepinephrine Reuptake Inhibitor as a Treatment for Meniere Disease: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39235772. doi:10.1001/jamaoto.2024.2241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。